On October 19, 1943 C.E., a 23-year-old PhD student working in a basement laboratory at Rutgers University pulled a sample from a soil culture and changed the course of medicine. Albert Schatz had just isolated streptomycin — the first antibiotic capable of killing the bacterium behind tuberculosis, a disease that had claimed more human lives than almost any other in recorded history.
Key findings
- Streptomycin isolation: Schatz extracted the compound from Streptomyces griseus, a soil-dwelling microorganism, in October 1943 C.E. — the first antibiotic shown to be active against tuberculosis.
- Tuberculosis treatment: Before streptomycin, TB had no reliable cure; it killed roughly one in seven people in industrialized nations throughout the 19th and early 20th centuries C.E.
- Randomized clinical trial: The first randomized trial of streptomycin against pulmonary TB, conducted from 1946 to 1948 C.E. by the U.K.’s Medical Research Council, is now widely recognized as one of the first randomized curative trials in the history of medicine.
A cure born in the soil
Tuberculosis is ancient. Evidence of the disease appears in Egyptian mummies and in bones from Neolithic Europe. For millennia, it killed quietly and steadily — in the lungs, the spine, the lymph nodes — and medicine had almost nothing to offer in return.
That changed when scientists began looking seriously at soil microbes. Selman Waksman, Schatz’s doctoral supervisor at Rutgers University, had spent decades studying actinomycetes — a group of bacteria found in soil that naturally produce compounds lethal to other microbes. His lab had already identified several such compounds, though none effective against TB. Schatz, working with urgency and little funding, screened hundreds of cultures before isolating Streptomyces griseus and extracting streptomycin from it.
The Rutgers team published their findings in January 1944 C.E. Within months, they were collaborating with researchers at the Mayo Clinic to begin animal trials. A study using just 10 grams of the scarce drug in guinea pigs demonstrated survival — enough to convince Merck & Co. to redirect resources toward commercial production.
How streptomycin works
Streptomycin belongs to a class of antibiotics called aminoglycosides. It works by binding irreversibly to the 30S ribosomal subunit of bacterial cells — essentially jamming the machinery bacteria use to manufacture proteins. Without functioning protein synthesis, the cell cannot survive.
At low concentrations, streptomycin targets bacterial ribosomes without fatally disrupting human cells, though the margin is narrow enough that side effects — particularly hearing loss and kidney toxicity — are real risks. Those risks were accepted, in the 1940s C.E., as vastly preferable to TB’s near-certain death sentence.
The World Health Organization now lists streptomycin as an essential medicine and classifies it as critically important for human medicine — recognition that its core function remains relevant even in an era of far newer drugs.
Lasting impact
The isolation of streptomycin did more than cure TB. It proved that antibiotics were not a one-off phenomenon — that the natural world contained a vast pharmacopeia waiting to be found in soil, in fungi, in the microbial communities beneath our feet. The search for new antibiotics intensified, and the discipline of soil microbiology gained new urgency and prestige.
The Medical Research Council’s streptomycin trial of 1946–1948 C.E. also left a methodological legacy as significant as the drug itself. Its use of random allocation to treatment and control groups helped establish the randomized controlled trial as the gold standard of medical evidence — a framework that now underlies virtually all clinical medicine.
Robert Dole, who later served as U.S. Senate Majority Leader and ran for president, was the third patient treated with streptomycin at a military hospital in Battle Creek, Michigan, in March 1946 C.E. He experienced what the historical record describes as a rapid and robust recovery — a detail that grounds this milestone in individual human lives, not just statistics.
TB mortality fell dramatically in the decades that followed. The U.S. Centers for Disease Control and Prevention tracks ongoing progress in TB elimination, a goal that streptomycin made conceivable for the first time in human history.
Blindspots and limits
The Nobel Prize in Physiology or Medicine was awarded in 1952 C.E. to Selman Waksman alone — a decision that erased Schatz’s name from history for decades. Schatz sued for recognition and a share of the royalties; he eventually received 3% and back compensation, but the Nobel committee never revisited the award. Elizabeth Bugie, who contributed meaningfully to the lab’s work on antimicrobials and co-authored the original paper, was not listed on the patent and received a 0.2% royalty share — a reminder that scientific credit has rarely been distributed equitably, particularly for women researchers.
Streptomycin also came with a problem built into its success: bacterial resistance. Early clinical trials showed that Mycobacterium tuberculosis could develop resistance to the drug, particularly when it was used alone. That finding drove the development of combination therapy — using multiple drugs simultaneously — which remains the cornerstone of TB treatment today. TB still kills more than a million people each year globally, and drug-resistant strains pose a serious ongoing threat.
Read more
For more on this story, see: Wikipedia — Streptomycin
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on the modern era
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-

Renewables hit 49% of global power capacity for the first time
Renewable energy capacity crossed a landmark threshold in 2025, with global installed power surpassing 5,100 gigawatts and representing 49% of all capacity worldwide for the first time in history. The International Renewable Energy Agency reported a single-year addition of 692 gigawatts, led overwhelmingly by solar power, which alone accounted for 75% of new renewable installations. Clean energy now represents 85.6% of all new power capacity added globally, signaling that the transition has moved from aspiration to economic reality. The milestone carries implications beyond climate — nations with strong renewable bases demonstrated measurably greater energy security amid ongoing geopolitical instability.
-

Global suicide rate has dropped nearly 40% since the 1990s
Global suicide rates have dropped nearly 40% since the early 1990s, falling from roughly 15 deaths per 100,000 people to around nine — one of modern public health’s most significant and underreported victories. This decline was driven by expanded mental health services, crisis intervention programs, and proven strategies like restricting access to lethal means. The progress spans dozens of countries, with especially sharp declines in East Asia and Europe. Critically, this trend demonstrates that suicide is preventable at a population level — making the case for sustained investment in mental health infrastructure worldwide.
-

Rhinos return to Uganda’s wild after 43 years of absence
Uganda rhino reintroduction marks a historic milestone: wild rhinoceroses are roaming Ugandan soil for the first time in over 40 years. In 2026, rhinos bred at Ziwa Rhino Sanctuary were released into Kidepo Valley National Park, ending an absence caused entirely by poaching and political collapse during the Idi Amin era. The release represents decades of careful breeding, conservation funding, and community engagement. For local communities, conservationists, and a watching world, it proves that deliberate, sustained human effort can reverse even the most painful wildlife losses.

